StefanSchneider

Partner

Munich + 49.89.20.60.42.200

Contact

Partager

Stefan Schneider is a private equity and venture capital lawyer with more than 18 years of experience advising investors, businesses, and managers on complex domestic and multinational transactions. He advises on and negotiates buyouts and minority investments, early to late-stage financing rounds, mergers, divestments, carve-outs, shareholder agreements, management equity programs, and corporate reorganizations.

Stefan recently advised on ARCHIMED's acquisitions of PlasmidFactory and Cube Biotech; CDPQ's investment in Hy2gen AG; and Sateba's disposal of its German concrete sleeper business. In the early-stage arena, Stefan advised on Portage's investment in Quin and Tikehau's investments in VMRay and Build38. He also advises growth companies on corporate and commercial matters.

Prior to joining Jones Day in May 2009, Stefan worked more than four years in the Munich and New York offices of a major U.S. law firm. He is a member of the Rechtsanwaltskammer München (Munich Bar) and the German Bar Association and its Firm Management Working Group.

Expérience

  • Affiliates of Centre Lane Partners acquire substantially all of the assets of Hardinge Inc. and its subsidiaries, including the Kellenberger, USACH, SuperPrecision, and Workholding business linesJones Day advised affiliates of Centre Lane Partners in the acquisition of substantially all of the assets of Hardinge Inc. and its debtor subsidiaries, a global leader and provider of advanced machine tool, manufacturing and workholding solutions, as part of chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware.
  • Jolt Capital leads €20 million financing of EVUM MotorsJones Day advised Jolt Capital, an independent private equity firm that specializes in Growth Capital Technology investments, in the €20 million Series B financing of EVUM Motors GmbH, a Munich-headquartered growth company and manufacturer of all-electric commercial vehicles.
  • LaSalle forms JV with Swiss Life Asset ManagersJones Day advised LaSalle Investment Management on a German-focused logistics real estate joint venture with Swiss Life Asset Managers.
  • Affinity Partners leads €207 million Series F financing of EGYMJones Day represented Affinity Partners in its acquisition of an interest in EGYM, a global fitness technology and corporate health innovation leader, in a Series F financing of €107 million, with an additional €100 million available for future investments.
  • Elaia Partners leads €3.6 million seed financing of hema.toJones Day advised Elaia Partners in connection with the €3.6 million seed financing of hema.to, a Munich-based medtech startup developing an artificial intelligence software dedicated to blood cancer diagnostic.
  • Real Alloy sells European business to SpeiraJones Day advised Real Alloy Holding, LLC in the sale of its European aluminum and magnesium recycling operations to Speira GmbH, an affiliate of KPS Capital Partners.
  • Stellex completes buyout of David Brown Santasalo GroupJones Day advised Stellex Capital Management LLC on its buyout of DB Santasalo S.à r.l from N4 Partners.
  • Tikehau Capital leads €13 million Series A funding of Build38 GmbHJones Day advised Tikehau Capital as lead investor in the €13 million Series A financing of Build38 GmbH, a leading provider of mobile application protection solutions that combine AI-powered threat intelligence and the strongest app shielding technology, with subsidiaries in Spain and Singapore.
  • Tikehau Capital leads Series B financing of VMRayJones Day advised Tikehau Ace Capital in leading alongside NRW.Bank and Gründerfonds Ruhr the Series B financing of VMRay, a global player in advanced threat detection and analysis that offers solutions for enterprises, governmental organizations, and MDRs to detect and analyze the most challenging malware and phishing threats.
  • FleetCor acquires PlugsurfingJones Day advised FleetCor Technologies, Inc. in the acquisition of Plugsurfing, a leading European electric vehicle (EV) software and network provider.
  • ArchiMed acquires PlasmidFactoryJones Day advised ArchiMed, a leading trans-atlantic private equity healthcare specialist, on its acquisition of PlasmidFactory, a globally renowned high-quality producer of plasmid DNA with strong research capabilities, from IP due diligence to structuring of acquisition and rollover re-investment.
  • Portage Ventures (Sagard) leads $15 million Series A funding round of getquinJones Day represented Portage Ventures (Sagard), with participation from Horizons Ventures, embedded/capital and sino AG and angel investors such as N26 founder Maximilian Tayenthal and Scalable Capital founder Erik Podzuweit, in the $15 million Series A financing round of getquin, a social network for discussing and analyzing stocks, cryptocurrencies, and other investment opportunities.
  • CDPQ participates in record investment in Hy2genJones Day advised Caisse de dépôt et placement du Québec (CDPQ) on its participation in the record €200 million investment in green hydrogen pioneer Hy2gen AG, the world’s largest private investment in green hydrogen to date.
  • Aurelius sells remaining Office Depot Europe business to strategic buyer RAJA GroupJones Day advised AURELIUS Equity Opportunities in the sale of Office Depot Europe, which includes the remaining Viking and Office Depot Europe activities to strategic buyer RAJA Group.
  • Alliance Ventures invests in The Mobility House AGJones Day advised Alliance Ventures, the strategic venture capital arm of Renault-Nissan-Mitsubishi, in connection with its Series C investment in The Mobility House AG, a technology company that provides a platform for integrating vehicle batteries into power grids using intelligent charging, energy and storage solutions.
  • ArchiMed acquires Cube Biotech GmbHJones Day advised ArchiMed, a leading Trans-Atlantic private equity healthcare specialist, on its acquisition of Cube Biotech GmbH, a leading provider of expression, purification, and crystallization services and products for membrane proteins.
  • Cardinal Health sells its Cordis business to Hellman & Friedman for approximately $1 billionJones Day advised Cardinal Health in connection with the divestiture of its Cordis business to Hellman & Friedman for approximately $1 billion.
  • EMERAM Capital Partners sells portfolio company MEONA to Trill ImpactJones Day represented EMERAM Capital Partners GmbH, one of the leading investment companies for medium-sized companies in the German-speaking region, in the sale of its portfolio company MEONA, an innovation leader for clinical software, to the private equity firm, Trill Impact.
  • Wellington Partners, MIG GmbH & Co. Fonds 16, and Salvia GmbH invest €15 million in growth financing of Creative BalloonsJones Day represented Wellington Partners Life Sciences V, a leading European Venture Capital firm investing in early- and growth-stage Life Science companies, together with MIG GmbH & Co. Fonds 16 and Salvia GmbH, in connection with their €15 million growth investment in Creative Balloons GmbH, a specialist in researching and developing ultra-thin polyurethane (PUR) balloons for medical device applications, namely catheter manufacturing.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.

    • Representative transactions prior to joining Jones Day:

    Advised Dura Automotive Germany in a secured lending matter.

    Advised Infor Global Solutions with respect to its corporate reorganization, corporate litigation, and a number of acquisition finance matters.

    Advised Monomoy Capital Partners regarding the acquisition of the Katun group.

    Advised a portfolio company of private equity investor Findos regarding the sale of a business branch.

    Advised a consortium of Goldman Sachs Private Equity, Cerberus, and Credit Suisse on the management equity program of a portfolio company.

    Advised private equity investor Gilde Buy-Out Partners regarding the acquisition of the Hofmann Menü Group from HgCapital.

    Advised private equity investor Findos regarding the acquisition of Ondal Industrietechnik GmbH and Tondeo-Werke GmbH from Wella AG.

    Advised private equity investor Bain Capital regarding the acquisition of the Ideal Standard Group for US$1.76 billion and represented Ideal Standard Germany in its corporate reorganization.

    Advised Sara Lee regarding the sale of its world-wide Branded Apparel Business to Sun Capital Partners.

    Advised private equity investor Oaktree Capital Management regarding the acquisition of the pan-european ice-cream business from Roncadin S.p.A. for €152.5 million and the establishment of a management equity program.

    November 2024 Handout

    Energy Transition and Social Infrastructure

    November 2024 Handout

    Energy Transition in the Construction and Infrastructure Industry

    December 2023 Alert

    EU Strikes Political Deal on Landmark Artificial Intelligence Act

    April 2023 Podcast

    JONES DAY TALKS®: The Rise of AI Regs: Approaches from the European Union and United States

    February 2023 Alert

    Better Together: U.S. and EU Enter Artificial Intelligence Collaboration Agreement

    April 2021 Commentary

    Regulating Artificial Intelligence: European Commission Launches Proposals

    April 2020 Commentary

    IP Protection of Artificial Intelligence in Europe: Tailor-Made Solutions Required

    October 2018 Commentary

    Game Changer for Cryptocurrency in Germany? Court Holds No License Required to Trade Bitcoins

    October 2018 Commentary

    ICOs and Token Regulation from a German Perspective

    Autres publications

    • October 2009
      Mehr Rechtssicherheit für Wandelanleihen, VentureCapital Magazin

    Avant d’envoyer cet e-mail, veuillez prendre note de ce qui suit :

    Les informations contenues sur le site www.jonesday.com sont destinées à un usage général et ne constituent pas des conseils juridiques. L’envoi et la réception de cet e-mail n’ont pas pour effet de créer une relation avocat-client. Aucun envoi de votre part à un membre du Cabinet ne sera traité comme confidentiel ou protégé à moins que nous n’ayons donné notre accord pour vous représenter. En envoyant cet e-mail, vous confirmez avoir lu et compris la présente notification.